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There is considerable interest in expanding B cell-targeted therapies in human
autoimmune diseases. However, clinical trials in human primary biliary cholangitis (PBC)
using a chimeric antibody against human CD20 (hCD20) have showed limited efficacy.
Two potential explanations for these disappointing results are the appearance of anti-drug
antibodies (ADAs) and the high frequency of patients with moderate PBC or patients who
had failed ursodeoxycholic acid treatment. Here, we studied a novel humanized IgG1
antibody against hCD20 and explored its efficacy in early stage PBC using a well-defined
murine model. We developed a unique murine model consisting of dnTGF-βRII mice
expressing hCD20 and human Fcγ receptors (hFcγRs). Beginning at 4–6 weeks of age,
equivalent to stage I/II human PBC, female mice were given weekly injections of an
anti-hCD20 antibody (TKM-011) or vehicle control, and monitored for liver histology as
well as a broad panel of immunological readouts. After 16 weeks’ treatment, we observed
a significant reduction in portal inflammation, a decrease in liver-infiltrating mononuclear
cells as well as a reduction in liver CD8+ T cells. Importantly, direct correlations between
numbers of liver non-B cells and B cells (r = 0.7426, p = 0.0006) and between numbers
of liver memory CD8+ T cells and B cells (r = 0.6423, p = 0.0054) were apparent.
Accompanying these changes was a dramatic reduction in anti-mitochondrial antibodies
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(AMAs), interleukin (IL)-12p40 and IL-5, and elevated levels of the anti-inflammatory
chemokine CXCL1/KC. In mice that developed ADAs, clinical improvements were less
pronounced. Sustained treatment with B cell-targeted therapies may broadly inhibit
effector pathways in PBC, but may need to be administered early in the natural history
of PBC.
Keywords: anti-drug antibodies (ADAs), anti-mitochondrial antibodies (AMAs), B cell depletion therapy, human
anti-chimeric antibodies (HACAs), humanized anti-human CD20 antibody, mouse anti-human antibodies (MAHAs),
primary biliary cholangitis (PBC)
INTRODUCTION
The destruction of biliary epithelial cells (BECs) in patients with
primary biliary cholangitis (PBC) is at least partially secondary
to development of autoreactive CD8+ T cells (1–3). In addition,
there is evidence that B cells and serum anti-mitochondrial
antibodies (AMAs) exacerbate biliary pathology through their
effects on apoptotic biliary cells as well as through B-cell
regulatory mechanisms; inflammatory liver infiltrates include B-
cell foci (4). Although there is no direct correlation between
AMA titer and disease severity, a variety of data support a
role of B cells in the immunopathology of PBC (5–10). For
example, dimeric IgA-AMA complexes facilitate induction of
BEC apoptosis (8) and AMAs enhance cross-presentation and
generation of pyruvate dehydrogenase complex-E2 (PDC-E2)-
specific cytotoxic T cell responses in the presence of PDC-E2-
pulsed antigen-presenting cells (5). In combination with AMAs,
unmodified PDC-E2 localized in apoptotic BECs facilitates
production of proinflammatory cytokines from monocyte-
derived macrophages in PBC (6, 7). These results have led us to
postulate that the cellular responses involved in loss of tolerance
and biliary pathology include contributions from both B and T
cells and that biliary destruction is an orchestrated multi-lineage
response (11).
We have previously reported the use of dominant negative
TGF-β receptor II (dnTGF-βRII) mice as a model for human PBC
(12). The expression of dnTGF-βRII is limited to selected cell
lineages including CD4+, CD8+, and CD1d-restricted natural
killer T (NKT) cells; B cell function is normal in this model (12,
13). We previously demonstrated that treatment of juvenile mice
with a monoclonal anti-mouse CD20 antibody was effective in
preventing PBC, but that responses were reduced when treatment
was initiated in older mice (14). This may reflect a limited
contribution by B cells in the pathology of advanced bile duct
damage during human PBC (15).
There is considerable interest in expanding B cell-targeted
therapies for human autoimmune diseases (16–27). A chimeric
antibody against human CD20 (hCD20), rituximab, showed
limited clinical efficacy in human PBC (28–30). One explanation
Abbreviations:Ab, antibody; ADA, anti-drug antibody; AMA, anti-mitochondrial
antibody; ADCC, antibody-dependent cell-mediated cytotoxicity; CDC,
complement-dependent cytotoxicity; CXCL1/KC, chemokine (C-X-C motif)
ligand 1/keratinocyte-derived chemokine; dnTGF-βRII mice, TGF-β receptor II
dominant negative mice; HACA, human anti-chimeric antibody; hCD20, human
CD20; hFcγR, human Fcγ receptor; IL, interleukin; MNC, mononuclear cell; PBC,
primary biliary cholangitis; TGF-β, transforming growth factor-β; TNF-α, tumor
necrosis factor-α.
for its limited efficacy was the appearance of anti-drug antibodies
(ADAs; more specifically, human anti-chimeric antibodies,
HACAs) as observed in other human autoimmune diseases
(31–37). Moreover, HACAs have been associated with adverse
events such as serum sickness (38–40). In this study, we
studied a novel humanized IgG1 antibody against hCD20
that is less immunogenic compared with chimeric antibodies,
enabling intermittent administration with much lower risk
of anti-humanized antibody development during treatment
of human PBC [Figure 1A; (41)]. This antibody (TKM-011,
formerly called BM-ca) has significant direct cytotoxic activity as
well as antibody-dependent cell-mediated cytotoxicity (ADCC)
activity, similar to rituximab and ofatumumab (42–44). To
better reflect human immunobiology, we generated dnTGF-
βRII mice expressing hCD20 as well as human Fcγ receptors
(hFcγRs) (Figure 1B). After treating these animals with the
humanized anti-hCD20 antibody, TKM-011, we observed a
significant reduction in portal inflammation, decreased liver-
infiltrating mononuclear cells and a reduction in liver CD8+ T
cells. Importantly, direct correlations were apparent between the
numbers of liver non-B cells and B cells and between the numbers
of liver memory CD8+ T cells and B cells. These effects were
less pronounced in mice that developed mouse anti-humanized
antibodies (MAHAs). These data suggest that the presence of
ADAs limits the effectiveness of B cell-targeted therapies and
might be overcome by using fully humanized antibodies.
MATERIALS AND METHODS
Generation of hCD20- and
hFcγR-Expressing IL-10-GFP dnTGF-βRII
Mice
Human CD20 and FcγR bacterial artificial chromosome
(BAC) transgenic mice were generated by the Institute of
Immunology Co., Ltd. (Tokyo, Japan) as follows. All in vivo
experiments and protocols for animal studies were approved
by the Laboratory Animal Ethics Committee at Institute of
Immunology Co., Ltd. The RP11-792H2 (human) and RP23-
117H19 (mouse) BAC clones were selected for construction
of a chimeric human-mouse CD20 gene. A hFcγR BAC
clone, RP11-925D6, was selected because its 180-kb complete
sequence contained the hFcγR gene cluster including the
activating FcγRs (FcγR2A, FcγR3A, FcγR2C, and FcγR3) and
the inhibitory FcγR2B. A chimeric human-mouse CD20 BAC
construct harboring the full-length hCD20 coding region in place
of the mouse ortholog was generated by BAC recombineering
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FIGURE 1 | Study design. (A) Undesirable immune responses result in
development of anti-drug antibodies (ADAs) against therapeutic monoclonal
antibodies. Specific regions of chimeric antibodies (murine variable and human
constant regions) and humanized antibodies (human with murine
complementary-determining regions, CDRs) are immunogenic in humans and
mice, and are targeted by human anti-mouse antibodies (HAMAs) including
human anti-chimeric antibodies (HACAs) and mouse anti-human antibodies
(MAHAs) in humans and mice, respectively. (B) Working mechanisms of the
humanized anti-human CD20 mAb, TKM-011, in human CD20 (hCD20)-,
(Continued)
FIGURE 1 | and human FcγR (hFcγR)-expressing mice. Genetic modification
enabled hCD20 and hFcγR expression under the control of mouse CD20 and
mouse FcγR promoters, respectively. TKM-011 binds to hCD20 and is
captured by hFcγR-expressing cells, leading to B-cell elimination mediated by
antibody-dependent cell-medicated cytotoxicity (ADCC). (C) Mice expressing
hCD20 and hFcγR were injected with 250 µg of TKM-011 or 250 µL of PBS
intraperitoneally every week beginning at 4–6 weeks of age. Peripheral blood
was drawn for serum collection and lymphocyte analyses biweekly prior to
each treatment. Mice were sacrificed after 16 weeks of treatment, and their
tissues were used for pathological evaluation and flow cytometric analyses.
using the Red/ET Counter Selection BAC Modification Kit
(Gene Bridges, Heidelberg, Germany). The human-mouse CD20
BAC and human FcγR BAC constructs were prepared using
a Nucleobond Plasmid Purification Kit (MACHEREY-NAGEL,
Düren, Germany). For microinjection, both BAC constructs were
linearized with PI-SceI endonuclease (New England Biolabs,
Beverly, MA). The linearized BAC DNA was separated using
pulsed field gel electrophoresis, extracted by electroelution and
dialyzed against TE buffer containing 0.1mM EDTA. The BAC
transgenic mice were generated by pronuclear injection of
both the hCD20 and hFcγR BAC constructs into C57BL/6J
(B6) mouse embryos. Transgenic founders and germline
transmission of the BAC transgenic constructs were confirmed by
Southern blotting. No obvious gross phenotypic differences were
apparent between transgene-positive and -negative littermates.
Because hCD20- and hFcγR- expressing mice have functional
antibody-dependent cell-mediated cytotoxicity (ADCC) when
administered chimeric and humanized anti-hCD20 antibodies
(Supplementary Figure 1), several transgenic founders were
bred with wild-type B6 mice.
In the next phase of transgenic mouse construction,
hCD20- and hFcγR-expressing IL-10-GFP dnTGF-βRII mice
were generated as follows. First, dnTGF-βRII mice and IL-
10-GFP mice (from The Jackson Laboratory) were bred with
B6 mice. We also utilized the IL-10-GFP mice (12, 45,
46) to construct hCD20/hFcγR-expressing IL-10-GFP dnTGF-
βRII mice. Briefly, male IL-10-GFP expressing dnTGFβ-RII
mice were bred with female hCD20/hFcγR BAC transgenic
mice (Supplementary Figure 2) to obtain female heterozygous
dnTGFβ-RII mice expressing heterozygous hCD20, hFcγR and
IL-10-GFP (hCD20 and hFcγR-expressing IL-10-GFP dnTGF-
βRII mice). Of note, heterozygous hCD20 expression was
intentionally designed to promote incomplete B-cell depletion
when targeting hCD20 (Supplementary Figure 2A). Residual B
cells presumably remain after MAHA production against CD20-
targeted antibodies allow us to better evaluate the therapeutic
efficacy of anti-hCD20 treatment for liver inflammation in the
presence or absence of MAHAs. Throughout these studies, only
female mice were used and all animals were genotyped to confirm
the presence of dnTGF-βRII, hCD20, hFcγR, and IL-10-GFP
in genomic DNA at 3–4 weeks of age (45). All mice were
fed with sterile standard mouse chow CRF-1 (Charles River
Laboratories Japan, Tokyo, Japan) and filtered water and were
maintained under specific pathogen-free conditions. This study
was performed under a protocol approved by the Institutional
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Animal Care and Use Committee of Akita University Graduate
School of Medicine and Faculty of Medicine.
Experimental Protocol
An optimized dose of the humanized anti-hCD20 monoclonal
antibody TKM-011 (250 µg in 250 µL of PBS) or 250 µL of
PBS alone was administered intraperitoneally to hCD20- and
hFcγR-expressing IL-10-GFP dnTGF-βRII mice using a 26-gauge
needle every week starting at 4–6 weeks of age. Peripheral blood
samples from individual mice were obtained from the tail vein
prior to initial treatment and biweekly thereafter (Figure 1C).
Sera were collected and stored at−70◦C until use. Cells were used
for flow cytometric analyses of peripheral lymphocyte frequency.
Mice were sacrificed after 16 weeks of treatment, and tissues
(liver, spleen, and colon) and cells were used for pathological and
flow cytometric evaluation, respectively.
ELISA
Serum levels of murine IgG, IgA, and IgM as well as human IgG1
(hIgG1; TKM-011) were measured using mouse IgG, IgA, and
IgM quantitative ELISA kits (BETHYL, Montgomery, TX) and
a Human IgG1 Ready-SET-Go!TM kit (eBioscience, San Diego,
CA), respectively. Standards provided by the manufacturers
were used throughout. Serum reactivity of AMAs, anti-TKM-
011 antibodies, and anti-infliximab antibodies was quantified
using an ELISA Starter Accessory Kit (BETHYL, Montgomery,
TX). Briefly, 96-well ELISA plates were coated with either (i)
an affinity-purified recombinant fusion protein, pML-MIT-3,
which included three distinct lipoyl domains of PDC-E2, the
branched-chain 2-oxo-acid dehydrogenase complex, and the 2-
oxo glutarate dehydrogenase complex (47), (ii) TKM-011, and
(iii) infliximab as an irrelevant control. Briefly, ELISA plated were
coated with antigens at 5µg/mL in the manufacture provided
coating buffer at 4◦C overnight, washed three times with the
manufacture provided washing buffer, and blocked with the
manufacture provided blocking buffer for 30min. Sera (100 µL
volume; diluted between 1:200 and 1:40,000) were added to wells
of microtiter plates for 1 h at room temperature and the plates
were washed again. Horseradish peroxidase-conjugated goat
anti-mouse immunoglobulin (100 µL; diluted 1:2,000; Thermo
Fisher Scientific, Rockford, IL) was added to each well for 1 h
at room temperature, and the wells were washed three times.
Immunoreactivity was detected by measuring the optical density
(OD) at 450 nm after incubating for 15min with 100 µL of
3,3′,5,5′–tetramethylbenzidine and the reaction terminated with
of 100 µL of 2N sulfuric acid. Previously-calibrated positive and
negative standards were included in each assay. An OD ratio
of anti-TKM-011 to anti-infliximab reactivity was calculated for
each serum sample.
Flow Cytometry
Peripheral blood mononuclear cells (MNCs) were isolated
from heparinized murine blood using Histopaque-1.083 (Sigma-
Aldrich, Saint Louis, MO) to assess the frequency of B
and T cells. Cells were pre-incubated with mouse FcR
blocking reagent for 15min and then incubated at 4◦C for
20min with a pre-determined optimized concentration of PE-
conjugated anti-TCR-β (BioLegend) and APC-conjugated anti-
CD19 (BioLegend) antibodies. In addition, MNCs were isolated
from liver and spleen suspensions as previously described (12, 14,
48). An aliquot of these cells was pre-incubated with FcR blocking
reagent and then incubated at 4◦C with a combination of
fluorochrome-conjugated antibodies, including PE-conjugated
anti-CD44 antibody (BioLegend), PE-CF594-conjugated anti-
CD4, anti-CD8a and anti-CD19 antibodies (BD biosciences, San
Jose, CA), PE-Cy5 conjugated anti-TCR-β antibody (BioLegend),
and PE-Cy7-conjugated anti-CD4, anti-CD5, anti-CD8a, and
anti-NK1.1 antibodies (BioLegend). Multi-color flow analyses
were performed using an Accuri C6 cytometer (BD Biosciences,
San Jose, CA) and a Cytomics FC500 flow cytometer (Beckman
Courter, Brea, CA) using five-color analysis. The acquired
data were analyzed with Accuri C6 cytometer software (BD
Biosciences, San Jose, CA) and FlowJo (Ver10.1) software
(FlowJo, Ashland, OR).
The following cytokines, chemokines, and growth factors were
analyzed. Serum levels of eotaxin, G-CSF, GM-CSF, IFN-γ, IL-1α,
IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12(p40), IL-
12(p70), IL-13, IL-17A, KC(CXCL-1), MCP-1(MCAP), MIP-1α,
MIP-1β, RANTES, and TNF-α were quantified using a Bio-Plex
Pro Mouse Cytokine 23-Plex Immunoassay (Bio-Rad, Hercules,
CA) according to the manufacturer’s protocol. Sera were diluted
four or five times and then assayed.
Tissue Pathology and
Immunohistochemistry
Portions of liver, spleen and colon tissue were excised and
immediately fixed with 10% buffered formalin solution for 2
days at room temperature. Paraffin-embedded tissue sections
were then cut into 4-µm slices for routine hematoxylin (Merck
KGaA, Darmstadt, Germany) and eosin (Muto Pure Chemicals,
Tokyo, Japan) (H&E) staining. Scoring of liver inflammation was
performed for coded H&E-stained liver sections using a set of
six indices by a “blinded” pathologist (KT); the indices included
severity and frequency of portal and lobular inflammation
(evaluated as 0 = none, 1 = minimal, 2 = mild, 3 = moderate,
and 4 = severe inflammation) and bile duct damage (evaluated
as 0 = none, 1 = epithelial damage with cytoplasmic change,
2 = epithelial damage with nuclear change, 3 = chronic non-
suppurative destructive cholangitis, and 4 = bile duct loss).
Frequencies were scored as 1 = none, 2 = 1–10%, 3 = 11–
20%, 4 = 20–50%, and 5 = more than 50% frequency. The final
scores for portal and lobular inflammation and bile duct damage
were calculated as the sum total of the indices for severity and
frequency. Liver fibrosis was evaluated as 0 = none, 1 = portal
enlargement, 2= bridging fibrosis, 3= frequent bridging fibrosis
and, 4 = cirrhosis. Liver granuloma was evaluated as 0 = none,
1 = a few, 2 = portal or lobular, 3 = portal and lobular, and
4 = marked. Colon inflammation was evaluated as 0 = none,
1 = minimal, 2 = mild, 3 = moderate, and 4 = severe
inflammation (crypt abscess).
Tissue sections were cut at 4-µm thickness from tissue blocks
and placed on slides. After de-paraffinization, sections were
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soaked in a solution of 3% H2O2 in methanol for 5min to
block endogenous peroxidase, then in target retrieval buffered
saline solution (Dako Cytomation, Carpinteria, CA) in a non-
metal-containing plastic pressure cooker, and finally heated
in a microwave oven for 10min (maximum 500W). After
heating, sections were washed with PBS for 2min and then
soaked in either a mixture of Mouse on Mouse Blocking
Reagent (Vector Laboratories, Burlingame, CA) and mouse FcR
Blocking Reagent (BioLegend) or Mouse on Mouse Polymer
IHC kit (Abcam; in cases where mouse antibodies were applied)
for 3 h. Primary antibodies were diluted to a previously-
determined optimized concentration in PBS, applied to the
tissue sections in a moist chamber and incubated overnight at
room temperature. After three washes with PBS, peroxidase-
conjugated polymer Envision kit for mouse primary antibodies
(Envision-PO, Envision System, Dako Cytomation) or Histofine-
PO for rat primary antibodies (Nichirei, Tokyo, Japan) was
applied to the appropriate specimens and incubated for 1 h
in the moist chamber. After washing five times with PBS,
the sections were immersed in 3,3-diaminobenzidine (DAB)
solution (Vector Laboratories), counterstained with hematoxylin
(Dako Cytomation) and mounted under coverslips. For double-
staining of mouse CD19 (mCD19) and hCD20 only, after
detecting mCD19 via the DAB reaction, the sections were soaked
in a mixture of Mouse on Mouse Blocking Reagent (Vector
Laboratories) and mouse FcR Blocking Reagent (BioLegend) as
described above. After PBS washes, anti-hCD20 antibody was
applied and incubated overnight in the moist chamber at room
temperature. After PBS washes, the Envision kits for mouse
and rabbit primary antibodies (Envision-AP, Envision System,
Dako Cytomation) were applied and incubated as described
above. After PBS washes, the sections were immersed in Fast Red
solution (Nichirei).
Statistical Analysis
Values were expressed graphically as means± standard deviation
(SDs). Differences were tested for significance using a two-
tailed unpaired Mann-Whitney test and paired Wilcoxon test
as appropriate, and associations between paired values were
examined using Pearson’s correlation and linear regression in
Prism (Ver. 7.0) software (GraphPad, La Jolla, CA). Values of p
< 0.05 were considered statistically significant.
RESULTS
Treatment With TKM-011 Resulted in
Reduced Frequencies of Peripheral B
Cells, but This Effect Was Attenuated
During the Latter Half of the Treatment
Period After the Emergence of
Anti-TKM-011 Antibodies
We monitored the frequencies of peripheral CD19+ B cells and
TCR-β+ T cells biweekly over the course of TKM-011 treatment.
As shown in Figures 2A,B, the frequency of CD19+ B cells
decreased by nearly half compared with baseline after 2 weeks
of treatment with TKM-011, and were significantly reduced
in TKM-011-treated mice during the first half of the TKM-
011 treatment period. In contrast, the frequency of peripheral
TCR-β+ T cells inversely increased in the former half, but
the increment was attenuated in the latter half of the TKM-
011 treated term. As similar to our previous observation (14),
the frequency of peripheral B cells decreased in control mice
after 10 weeks of treatment, possibly reflecting intense T cell
expansion after 12 weeks of age (unpublished data). Because
the increased frequency of peripheral B cells demonstrated
lower efficacy of TKM-011 in B-cell depletion during the latter
part of treatment (Figure 2B), we examined the presence of
anti-TKM-011 antibodies in the sera of TKM-011-treated mice
using indirect ELISA. Notably, the relative degree of serum
immunoreactivity against TKM-011, compared with infliximab
as a control, was significantly elevated after both 10 and 16 weeks
of treatment in 10 of 16 TKM-011-treated mice (Figure 2C).
Longitudinal data revealed that serum reactivity against TKM-
011 persisted in individual mice (Figure 2C). Furthermore,
serum levels of hIgG1 (presumably TKM-011) were examined at
6 weeks of treatment, when TKM-011 levels would be expected
to be substantially higher, as well as at 10 and 16 weeks. Serum
TKM-011 levels were significantly reduced during the latter
half of treatment, especially in anti-TKM-011 positive mice
(Figure 2C). Significant B-cell depletion was sustained longer
in anti-TKM-011 negative mice compared with anti-TKM-011
positive mice (Figure 2D). Taken together, these data suggested
that emergence of anti-TKM-011 antibodies was one factor
responsible for attenuating B-cell depletion in TKM-011-treated
mice.
TKM-011 Treatment Affected Serum Levels
of AMAs and Immunoglobulins
Because anti-TKM-011 antibodies attenuated B-cell depletion
and possibly minimized changes in serum immunoglobulins,
we analyzed the serum immunoglobulins of TKM-011-treated
mice (anti-TKM-011 positive and anti-TKM-011 negative mice
separately), and compared these with PBS-treated controls
(Figure 2). The sera of PBS-treated mice contained significant
levels of AMAs, which were reduced after 8 weeks of treatment
with TKM-011 (Figure 3). There was a significant decrease in
serum IgG at 8 and 16 weeks of treatment in anti-TKM-011
negative mice, but an increase in serum IgM at 16 weeks of
treatment (Figure 3), suggesting B cell recovery after depletion
in TKM-011 treated mice.
TKM-011 Treatment Ameliorates Liver
Inflammation in hCD20- and
hFcγR-Expressing IL-10-GFP dnTGF-βRII
Mice
After the 16-week treatment period, liver sections of TKM-011
treated mice exhibited significantly reduced liver inflammation.
The degrees of hepatic lobular and portal tract inflammation as
well as bile duct damage were plotted individually in Figure 4A.
TKM-011 treated mice demonstrated significantly milder portal
and lobular inflammation, and 2 of 9 TKM-011 treated mice
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FIGURE 2 | Peripheral B and T cell frequency over the treatment period. (A) Representative flow cytometry dot plots prior to the initiation and after 4 weeks of
treatment. TKM-011 treatment reduced the frequency of mouse CD19+ cells and reversibly increased TCR-β+ cells among peripheral mononuclear cells. (B) Time
course of frequency of CD19+ and TCR-β+ cells. The frequencies of CD19+ B and TCR-β+ T cells were significantly lower and higher, respectively, in
TKM-011-treated mice compared with controls. (C) The ratio of anti-TKM-011:anti-infliximab antibodies was examined in the sera of TKM-011- and PBS-treated mice
prior to treatment and at 10 and 16 weeks of treatment. The data are expressed relative to the cut-off value set as 1.0 (mean ± 3 SD of the OD ratio of PBS-treated
control mice). The time course of the OD ratio in each TKM-011-treated mouse was also indicated. Serum levels of human IgG1 (hIgG1) were examined in
TKM-011-treated mice at 6, 10, and 16 weeks of treatment. TKM-011-treated mice were differentiated by the presence (n = 10) or absence (n = 6) of anti-TKM-011
antibodies. (D) Time course and frequency of CD19+ B cells and TCR-β+ T cells shown separately in the presence or absence of anti-TKM-011 antibodies. A
significantly decreased frequency of CD19+ B cells was observed for a longer duration in anti-TKM-011 negative compared with anti-TKM-011 positive mice. [n = 20
PBS-treated and n = 16 TKM-011-treated mice, with the latter subdivided into n = 10 anti-TKM-011 positive mice, shown in red, and n = 6 anti-TKM-011 negative
mice, shown in blue. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 in Mann-Whitney test and Wilcoxon test for unpaired and paired samples, respectively, in
(B–D)].
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FIGURE 3 | Serum levels of anti-mitochondrial antibodies and immunoglobulins. The titer of anti-mitochondrial antibodies (AMAs) and the concentrations of serum
IgM, IgA, and IgG were examined prior to treatment and after 8 and 16 weeks of treatment. Serum AMA reactivity to the recombinant fusion protein MIT-3 was
significantly reduced after 8 weeks of TKM-011 treatment, especially in anti-TKM-011 negative mice. Serum levels of IgM were significantly increased in
TKM-011-treated mice, especially anti-TKM-011 negative mice, compared with controls after 16 weeks of treatment. Serum levels of IgA were not affected by
TKM-011 treatment. Serum levels of IgG were significantly reduced in anti-TKM-011 negative mice compared with PBS-treated control mice (n = 20 PBS-treated and
n = 16 TKM-011-treated mice, with the latter subdivided into n = 10 anti-TKM-011 positive mice, shown in red, and n = 6 anti-TKM-011 negative mice, shown in
blue. *p < 0.05, **p < 0.01 by Mann-Whitney test vs. PBS control).
showed no evidence of bile duct damage. Moreover, anti-TKM-
011 negative mice showed significantly less damage to bile ducts,
suggesting that TKM-011-induced B-cell depletion efficiently
attenuated autoimmune cholangitis in the absence of anti-TKM-
011 antibodies. Liver fibrotic changes were observed in 3 of
20 control mice and in 1 of 16 TKM-011 treated mice, but
not in any anti-TKM-011 negative mice (Figure 4B). Hepatic
inflammatory cell infiltrates were attenuated in TKM-011-treated
mice (Figure 4C). No granulomas were observed in either TKM-
011-treated or control mice. In a previous study, colitis was
exacerbated during treatment with an anti-mouse CD20 antibody
that induced total B-cell depletion (14). In this study, colonic
inflammation was not induced by the partial B-cell depletion
induced by TKM-011 treatment (data not shown).
Treatment With TKM-011 Reduced Levels
of Hepatic CD8+ T Cell Infiltrates in
hCD20- and hFcγR-Expressing IL-10-GFP
dnTGF-βRII Mice
The total number of MNCs both in the liver (1.582 ± 0.7486
vs. 2.465 ± 1.457 × 106/g liver, p = 0.0359) and spleen (5.000
± 2.480 vs. 6.792 ± 3.161 × 108/g spleen, p = 0.0091) were
significantly reduced after 16 weeks of TKM-011 treatment
(Figure 5A). Although the frequency of peripheral B cells was not
significantly different after 12 weeks of treatment (Figure 2B),
administration of TKM-011 for 16 weeks markedly reduced the
total numbers of CD8+ T cells (1.577 ± 0.8583 vs. 2.418 ± 1.254
× 105/g liver, p = 0.0494; 8.037 ± 3.935 vs. 13.06 ± 10.14 ×
107/g spleen, p= 0.0422) and numbers of activated CD8+ T cells
(1.386 ± 0.8159 vs. 2.275 ± 1.252 × 105/g liver, p = 0.0298;
6.325 ± 3.066 vs. 11.32 ± 9.095 × 107/g spleen, p = 0.0256)
in the liver and spleen (Figure 5A). In contrast, the numbers of
total and memory CD4+ T cells in the liver were unaffected by
TKM-011 treatment (7.172 ± 3.522 vs. 9.518 ± 9.298 × 104/g
liver, p = 0.9937; 6.206 ± 3.558 vs. 8.836 ± 9.414 × 104/g liver,
p = 0.9875), but were decreased in the spleen (5.064 ± 2.328
vs. 6.947 ± 2.222 × 107/g spleen, p = 0.0013; 3.264 ± 1.824 vs.
5.216 ± 2.014 × 107/g spleen, p = 0.0001) of TKM-011 treated
mice (Figure 5A). Importantly, there was a significant positive
correlation between liver MNC numbers and total and memory
CD8+ T cell numbers (r = 0.6806, p < 0.0001; r = 0.6886, p <
0.0001), splenic MNC numbers (r = 0.6533, p < 0.0001), total
and memory CD4+ T cell numbers (r = 0.4746, p = 0.0034;
r = 0.5945, p = 0.0001), as well as total and memory CD8+ T
cell numbers (r = 0.6275, p < 0.0001; r = 0.6108, p < 0.0001;
Figure 5B). These findings suggested that liver CD8+ T cells
were not the only mediators of the liver pathology observed
in this mouse model of PBC, in agreement with a previous
report (49), and that both CD4+ and CD8+ T cells in the
spleen contribute to liver inflammation. In contrast, the changes
in number of hepatic CD4+ T cells did not correlate with the
changes in number of liver MNCs. Associations between liver
MNCnumbers and serum levels of immunoglobulins as well as of
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FIGURE 4 | PBC-like liver pathology was ameliorated in TKM-011 treated mice. (A) Liver pathological evaluation after 16 weeks of treatment to assess severity,
frequency and score in lobular, and portal inflammation as well as bile duct damage. The degree and frequency of portal and lobular inflammation, as well as score for
lobular inflammation, was significantly lower in TKM-011 treated mice compared with PBS-treated mice. The frequency of bile duct damage was significantly lower in
anti-TKM-011 negative mice. (B) Liver fibrotic changes were evaluated after 16 weeks of treatment, but were not observed in anti-TKM-011 negative mice. (C)
Hematoxylin and eosin (H&E)-stained representative liver sections after 16 weeks of treatment showing that TKM-011-treated mice display milder cellular infiltrates in
lobular and portal areas around interlobular bile ducts compared with PBS-treated mice. [n = 20 PBS-treated and n = 16 TKM-011-treated mice, with the latter
subdivided into n = 10 anti-TKM-011 positive mice, shown in red, and n = 6 anti-TKM-011 negative mice, shown in blue. CNSDC, chronic non-suppurative
destructive cholangitis; *p < 0.05, **p < 0.01 by Mann-Whitney test vs. PBS control in (A). In H&E stained sections, a black scale bar indicates 100µm in (C)].
Frontiers in Immunology | www.frontiersin.org 8 November 2018 | Volume 9 | Article 2534
Moritoki et al. Anti-hCD20 Antibody Ameliorates Murine PBC
FIGURE 5 | Immunological profiles of hepatic and splenic mononuclear cells (MNCs) in TKM-011-treated mice. (A) Absolute numbers of MNCs, CD4+ T, CD8+ T,
CD44hiCD4+ T, and CD44hiCD8+ T cells were enumerated per gram of liver and spleen tissue after 16 weeks of treatment. MNC reduction was evident both in liver
and spleen of TKM-011-treated mice. Numbers of liver CD8+ T cells and their activated subpopulation were significantly decreased in the livers of TKM-011-treated
mice along with an obvious reduction in the numbers of CD4+ T cells and their activated subpopulation in the spleen after TKM-011 treatment. (B) Pearson’s
correlation between number of liver MNCs with numbers of splenic MNCs, hepatic/splenic CD4+ T, CD8+ T, CD44hiCD4+ T, and CD44hiCD8+ T cells. Linear
regression is shown if correlations were apparent. (C) Pearson’s correlation and linear regression of liver MNC numbers with serum IgM levels. [n = 20 PBS-treated
and n = 16 TKM-011-treated mice, with the latter subdivided into n = 10 anti-TKM-011 positive mice, shown in red, and n = 6 anti-TKM-011 negative mice, shown in
blue. *p < 0.05, **p < 0.01, ***p < 0.001 by Mann-Whitney test vs. PBS control in (A), and for Pearson’s correlation analyses in (B,C)].
hIgG1 (TKM-011) were also assessed. IgM levels after 16 weeks of
TKM-011 treatment were negatively correlated with liver MNC
numbers (r = −0.3415, p = 0.0415; Figure 5C); no other serum
constituent (i.e., AMAs, IgA, IgG, or hIgG1) was significantly
correlated with MNC numbers (data not shown). The inverse
correlation between IgM levels and liver MNC frequency was
apparent in TKM-011-treated mice (r = −0.5044, p = 0.0463),
but not in control mice.
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Due to the minimal effect of TGF-β signaling on T and NKT
cells in this mouse model of PBC (12), the immunoregulatory
function of IL-10 could instead potentially attenuate liver
inflammation. We therefore examined the absolute numbers of
IL-10-GFP positive CD4+ T cells in the liver and the spleen,
but these were comparable in TKM-011-treated and control mice
(data not shown).
Treatment With TKM-011 Affected KC,
IL-12p40, and IL-5 Levels in Sera of hCD20-
and hFcγR-Expressing IL-10-GFP
dnTGF-βRII Mice
Serum levels of pro- and anti-inflammatory cytokines and
chemokines were examined extensively throughout the TKM-
011 treatment period. Mouse keratinocyte-derived chemokine
(KC, also known as the mouse IL-8 analog, CXCL1) is generally
thought to be a pro-inflammatory chemokine, but may have an
anti-inflammatory effect on liver inflammation in this model
and other murine models of other autoimmune diseases (50,
51). Serum levels of CXCL1/KC were higher after 8 weeks
of TKM-011 treatment compared with those of PBS-treated
mice (Figure 6). TKM-011-treated mice also demonstrated a
significant reduction in levels of the inflammatory cytokine, IL-
12p40. Moreover, levels of the B-cell and eosinophil-stimulating
cytokine, IL-5 were decreased after 16 weeks of TKM-011
treatment (Figure 6). Significantly reduced levels of TNF-α
and IL-13 were observed only in anti-TKM-011 positive mice
(Figure 6). None of the other cytokines and chemokines were
affected by TKM-011 treatment (data not shown).
The Immunohistochemical Profiles of B
Cells, hFcγR-Expressing Cells, and
hIgG1-Loaded Cells During Anti-TKM-011
Antibody Emergence
Seeing that anti-TKM-011 antibodies were sustained during
TKM-011 treatment (Figure 2C), we immunohistochemically
examined B cells, hFcγR-expressing cells, and hIgG1-loaded cells
in the liver and spleen of mice that were positive or negative for
anti-TKM-011 antibodies (Figures 7A,B). Singly mCD19+ and
hFcγR+ cells were invariably observed (Figures 7A,B), whereas
liver hCD20+mCD19+ double-positive cells were observed in
PBS-treated mice but not in anti-TKM-011 negative mice
(Figure 7A). On the other hand, fewer hCD20+ cells were
observed in the livers and spleens of anti-TKM-011 positive mice
(Figure 7A), whereas hIgG1+ cells were evident (Figure 7B).
This hIgG1+ cell population was not observed in anti-TKM-011
negative mice.
B Cells Are Crucial Directors of Non-B Cell
and CD8+ T Cell Liver Infiltrates in hCD20-
and hFcγR-Expressing IL-10-GFP
dnTGF-βRII Mice
Because hCD20+ cells were observed in the liver and spleen of
anti-TKM-011 positive mice, we next examined the numbers
of hepatic and splenic B cells as well as associations between
FIGURE 6 | Serum cytokine levels during TKM-011 treatment. Mean serum
cytokine levels were measured prior to treatment initiation and at 8 and 16
weeks of TKM-011 treatment using a Bio-Plex Pro Mouse Cytokine 23-Plex
Immunoassay. Keratinocyte-derived chemokine (KC) was significantly
increased in TKM-011 treated mice compared with controls after 8 weeks of
treatment. TKM-011 treatment reduced IL-12p40 and IL-5 levels after 16
weeks of treatment, whereas TNF-α and IL-13 levels were decreased in
anti-TKM-011 positive mice (n = 20 PBS-treated and n = 16
TKM-011-treated mice, with the latter subdivided into n = 10 anti-TKM-011
positive mice, shown in red, and n = 6 anti-TKM-011 negative mice, shown in
blue. *p < 0.05, **p < 0.01 by Mann-Whitney Test vs. PBS control).
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FIGURE 7 | Generation of anti-TKM-011 antibodies leads to incomplete depletion of hCD20-expressing cells. Representative liver and spleen sections of PBS-treated
and TKM-011-treated anti-TKM-011 positive and negative mice. Staining for human CD20+ (hCD20+), mouse CD19+ (mCD19+), hCD20+mCD19+
double-positive, human IgG1+ (hIgG1+), and human FcγR+ (hFcγR+) cells was performed. (A) Double-positive hCD20+mCD19+ cells detected in PBS-treated
mouse liver were indicated with green arrows, whereas no double-positive cells were observed in the livers of anti-TKM-011 negative mice. Representative
TKM-011-treated, anti-TKM-011 positive mice demonstrated hCD20+ cells in the portal area whereas CD19+ cells were numerously found in a serial liver section (red
arrows indicate hCD20+ cells). (B) In spleens of anti-TKM-011 positive mice, hCD20+ and hIgG1+ (i.e., TKM-011+) cells were also detected, whereas hFcγR
expression was the same in all groups.
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hepatic B cells and liver inflammatory cell infiltrates and between
hepatic B cells and splenic B cells. In TKM-011-treated mice,
absolute numbers of CD19+ B cells were significantly reduced
in the liver (1.594 ± 0.961 vs. 3.471 ± 2.426 × 105/g liver,
p = 0.0431) but not in the spleen (1.475 ± 1.058 vs. 2.267 ±
1.269 × 108/g spleen, p = 0.0878; Figure 8A). TKM-011-treated
mice also showed a trend toward decreased CD5+CD19+ B cells
in the liver and spleen (0.8471 ± 0.5212 vs. 1.853 ± 0.8007 ×
104/g liver, p = 0.0074; 1.204 ± 0.6144 vs. 2.102 ± 0.8967 ×
107/g spleen, p= 0.0431), although this did not achieve statistical
significance for CD5−CD19+ B cells (1.509 ± 0.9114 vs. 3.286
± 2.396 × 105/g liver, p = 0.0553: 1.354 ± 1.001 vs. 2.057
± 1.188 × 108/g spleen, p = 0.0878). We also examined the
absolute numbers of hepatic and splenic IL-10-GFP positive B
cells: these were not detectable in the liver, and their numbers
in the spleen were comparable between TKM-011-treated and
control mice (data not shown). Importantly, numbers of liver
CD19+ B cells was positively correlated with numbers of liver
CD19− MNCs (r = 0.7426, p = 0.0006), liver total and memory
CD8+ T cells (r = 0.6164, p = 0.0084; r = 0.6423, p = 0.0054),
and splenic CD19+ B cells (r = 0.7102, p = 0.0014; Figure 8B),
suggesting that B cells are crucial mediators of liver inflammation
and that B-cell depletion using anti-CD20 antibodies ameliorates
autoimmune cholangitis.
DISCUSSION
The significance of B cell in the immunopathology of
autoimmune cholangitis is well documented in patients with
PBC and animal models (6, 9, 10, 13, 15, 52–55). This study
demonstrated that B cells promote the development of PBC-
like liver disease, and partial but substantial B-cell depletion
with humanized anti-hCD20 antibody (TKM-011) effectively
attenuates bile duct damage in the hCD20 hFcγR-expressing
dnTGF-βRII mice. Specifically, we administered TKM-011
intraperitoneally weekly for 16 weeks to target peritoneal cavity
B cells as peripheral B cells (14, 56). Because hCD20 expression
is limited to 47.2 ± 4.6% of mCD19+ B cells in hCD20-
heterozygous mice (Supplementary Figure 2A), peripheral B
cells were significantly depleted 2 weeks after initial treatment
with TKM-011, but still retained at approximately 50% of the
initial frequency. Despite the limited B-cell depletion, TKM-011
treatment reduced the numbers of MNCs as well as total and
memory CD8+ T cells both in the liver and spleen. Splenic CD4+
T cells were also reduced in TKM-011-treated mice. Moreover,
our data demonstrated significant positive correlations between
numbers of liver CD8+ T cell populations with number of liver
MNCs. Using adoptive transfer, we previously demonstrated
that CD8+ T cells were the primary effectors for autoimmune
cholangitis in the dnTGF-βRII mice (49, 57, 58) and were
predominantly accumulate in the portal area (49). Also, we
previously observed a dramatic decrease in liver CD8+ T cells
as well as a non-inflamed liver pathology in 5 out of 7 mice after
a B cell depletion using anti-mouse CD20 antibody (14). In this
study, we observed significant reduction in liver inflammation,
and we noted that the number of hepatic CD8+ T cells positively
correlated with the numbers of liver MNCs as well as B cells,
including CD5+ and CD5− B-cell subsets. Majority of CD5+
B cells normally reside in peritoneal cavity and are poorly
susceptible for CD20-targeted B cell depleting treatment whereas
splenic CD5+ B cells are moderately susceptible but less than
other mature, T1, T2 andmarginal zone B cells (56). In this study,
a 16-weeks anti-CD20 weekly treatment significantly decreased
CD5+ B cells similarly in the liver and spleen. The reduction
in hepatic CD8+ T cells further suggests that incomplete but
substantial B-cell depletion still effectively attenuates hepatic
CD8+ T cell infiltrates in this mouse model. CD8+ T cells
proliferate to a greater extent in the presence of B cells activated
by anti-Ig and anti-CD40 compared with anti-CD3 stimulation
alone (59). CD40 ligand-stimulated B cells were able to potently
present antigens directly to naïve T cells in vivo, generating
CD8+ effector cells that secreted proinflammatory cytokines and
damaged target cells (60).
In autoimmune diabetic mice expressing hCD20, transient
treatment with a murine anti-hCD20 antibody delayed disease
onset, significantly depleted B cells, and reduced the frequency
of CD44+CD8+ memory T cells as well as the frequency of
repopulating B cells that express the co-stimulatory molecules
CD80/86 upon anti-CD40 stimulation (61). Taken together,
our data suggest that limited B cell depletion may sufficiently
suppress the development and expansion of mitochondrial
autoantigen-specific CD8+ T cells in this murine model of PBC
(58).
The magnitude of peripheral B-cell depletion was highly
significant during the middle of the treatment period but
dwindled toward its end. This observation can be accountable
by B cell recovery process in TKM-011-treated mice. In addition,
serum IgM levels decreased slightly during TKM-011 treatment,
but were significantly elevated after 16 weeks of treatment.
Although the level of serological IgM levels after 16 weeks of
treatment were negatively correlated with liver MNC numbers in
TKM-011 treated mice, the number of liver B cells was positively
correlated with liver non-B and CD8+ T cells. Thus, it is unlikely
that B-cell repopulation and/or proliferation occurred within the
liver.
We have previously observed elevated serum pro-
inflammatory cytokines in the dnTGF-βRII mouse model of PBC
(14, 52, 57). Here, we conducted a longitudinal analysis of an
extensive panel of serum cytokines and chemokines in TKM-011-
treated mice and control mice over the duration of treatment.
In this study, serum levels of KC significantly increased
during TKM-011 treatment (Figure 6). Overexpression and
administration of recombinant CXCL1/KC suppresses murine
autoimmune diseases such as experimental autoimmune
encephalomyelitis (51) and autoimmune myocarditis; in the
latter case treatment also reduced the numbers of autoreactive
effector T cells specific to cardiac self-peptides (50). CXCL1/KC
(also known as GRO-α) is a chemotactic factor for B cells (62). B
cells of younger individuals express higher levels of CXCL1/KC
when subjected to an inflammatory environment with LPS (63).
Moreover, intra-allograft B cells cultivated in vitro can potently
produce CXCL1/KC during chronic allograft damage after renal
transplantation (64). These reports suggest that KC released from
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FIGURE 8 | TKM-011 induced a reduction of liver B cells that was significantly correlated with CD19− liver cellular infiltrates. (A) Total B cells in the liver and CD5+ B
cells in the liver and spleen were significantly reduced after 16 weeks of TKM-011 treatment. (B) Pearson’s correlations between liver total CD19+, CD5+CD19+, and
CD5−CD19+ B cells and liver CD19− MNCs, CD8+ T, and CD44hiCD8+ T cells, as well as splenic total CD19+, CD5+CD19+, and CD5−CD19+ B cells were
examined. Linear regression was shown if a correlation was apparent. Liver total and CD5− B cell numbers were positively correlated with numbers of liver CD19−
MNCs and total and memory CD8+ T cells, while liver CD5+ B cell numbers were correlated with total and memory CD8+ T cell numbers. [n = 10 and 7 for PBS-
and TKM-011-treated mice, respectively. *p < 0.05, **p < 0.01 by Mann-Whitney test in (A), and for Pearson’s correlation analyses in (B)].
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inflammatory sites acts as not only an immunosuppressive agent
but also an enhancer of B-cell migration to inflammatory sites
and as a signal for migrant B cells to produce more CXCL1/KC.
IL-12p40 is one of the pro-inflammatory cytokines that was
elevated in the dnTGF-βRII mice (12) and depletion of IL-12p40
significantly ameliorated liver inflammation accompanied with a
reduction of the Th1 cytokine, TNF-α (65). In TKM-011 treated
mice, the level of serum IL-12p40 levels was markedly reduced
upon prolonged TKM-011 treatment at 16 weeks. Decreased
levels of a Th2 cytokine, IL-5, were also observed. In human PBC,
the presence of IL-5 is associated with eosinophilic cytotoxicity
in portal areas (66), and its secretion was significantly enhanced
upon in vitro T-cell receptor stimulation of CD8+CD57+ T cells;
the frequency of the CD45ROhigh subpopulation of these cells
was increased in early-stage PBC (67). In mice, IL-5 is as effective
as IL-2 in promoting cytotoxic T cell (CTL) responses, and both
CD8+ and CD4+ T cells in the spleen can produce IL-5 as well as
IL-2, TNF-α, and IFN-γ upon stimulation with specific antigen
(68). In the absence of IL-5, the frequency of CTL progenitors
was reduced in the spleens of immunized mice (68). Thus, B-cell
depletion upon TKM-011 treatment induced a decrease in both
hepatic and splenic CD8+ T cells as well as CD4+ T cells that led
to a decrease in serum IL-5, possibly inducing a delay in hepatic
CD8+ T-cell expansion.
Another Th2 cytokine, IL-13, exerts a pro-fibrotic effect on
infectious and autoimmune liver inflammation (69–71); however,
no significant reduction of fibrotic changes was observed
in TKM-011-treated mice (Figure 4B). Taken together, upon
continuous weekly treatment of TKM-011, decreased levels of
both IL-5 and IL-13 became evident and likely contributed to
the disease attenuation process in these animals. Our previous
work have demonstrated that depletion of B cells with anti-mouse
CD20 resulted in significant elevation in IL-6, amelioration of
liver inflammation but exacerbation of colon inflammation (14).
In contrast, IL-6 depletion exacerbated autoimmune cholangitis
in conjunction with hepatic B cell and CD8+ T cell accrual,
but ameliorated inflammatory bowel disease (72). In this study,
TKM-011 induced partial B-cell depletion which attenuated
autoimmune cholangitis, but neither affected the level of serum
IL-6 nor colon inflammation, suggesting that the degree of liver
inflammation was positively correlated with number of hepatic B
cells as long as IL-6 expression was stable.
IL-10-producing T and B cells, as well as serum levels of IL-
10, were similar in TKM-011-treated and control mice (data not
shown). Thus, it is unlikely that T cell-derived IL-10 play any
immune-regulatory function in the suppression of autoimmune
cholangitis after partial B-cell depletion using TKM-011.
The generation of ADAs is a critical immunopharmacological
concern in biologics therapeutics. ADA can form immune
complex, which further amplify ADA formation and hence poses
significant clinical consequences (73). The administration of
therapeutic TKM-011 antibody induced the development of anti-
TKM-011 antibodies in some mice and affected the serum levels
of TKM-011. We could not find any possible factors resulting
in non-development of anti-TKM-011 antibodies in the other
mice. However, in this study, we did not attempt to dissociate the
immunocomplexes of anti-TKM-011 antibodies with TKM-011
prior to our ELISA assay when we assayed for serum levels
of anti-TKM-011. This could have under-estimated the actual
amount of anti-TKM-011 antibodies in the samples. Although
a low titer of anti-TKM-011 antibodies may be present in anti-
TKM-011 negative mice, hCD20+mCD19+ double-positive cells
were not detected in either the liver or spleen of anti-TKM-
011 negative mice but hCD20+ cells were detected in anti-
TKM-011 positive mice. Because hFcγR+ cells were observed
in anti-TKM-011 positive mice at similar levels in negative and
control mice, anti-TKM-011 antibodies might prevent hFcγR-
expressing cells from binding TKM-011 (hIgG1) on hCD20+
cells, resulting in insufficient depletion of hCD20+ B cells
(Supplementary Figure 3).
In a pilot study in which rituximab given to PBC patients
who insufficiently responded to ursodeoxycholic acid, there was
a significant reduction of serum alkaline phosphatase (ALP),
AMA and IgM levels in some patients (29). Attenuation of
pruritus with rituximab was also observed in another PBC
cohort (28). On the other hand, other studies indicated that
rituximab was not effective in the management of fatigue
(74) but could transiently reduce or normalize the serum
levels of ALP in PBC patients (30). However, as a chimeric
antibody, rituximab carries the risk of inducing human
anti-chimeric antibodies (HACA) compared with humanized
antibodies (41). HACAs can impair B cell functions and decrease
its efficacy in human autoimmune disease treatments (31–
36). Indeed, the emergence of HACAs has been reported
in three of 13 PBC patients within 12 months of a two-
dose rituximab infusion, 2 weeks apart (28). Our results
suggest that conformational epitopes are immunogenic both
in the variable regions as well as in the constant regions
of hIgG1 in mice. Considering that the chimeric antibody
rituximab has been used in clinical studies for patients with
PBC (28–30), we also examined rituximab treatment using
the same protocol as TKM-011 in this PBC mouse model.
Although rituximab would be presumably less immunogenic
in mice compared with the humanized antibody TKM-011,
anti-rituximab antibodies developed in 6 out of 7 rituximab-
treated mice and no pathological improvement was observed
(Supplementary Figure 4). In addition, treatment with lower
doses (50 µg in 250 µL of PBS) of either TKM-011 or
rituximab was ineffective in ameliorating liver inflammation
(data not shown). Thus, in contrast with rituximab, TKM-011
treatment attenuated autoimmune cholangitis in this mouse
model of PBC. In humans, the mouse Ig variable regions in
chimeric antibodies are substantially immunogenic and can
generate ADAs (41). Therefore, humanized antibodies have an
advantage over chimeric antibodies. Optimization of dosage and
therapeutic protocols including intermittent administration in
clinical trials are needed for more comprehensive assessment of
humanized antibodies in autoimmune diseases therapy.
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Supplementary Figure 1 | Splenic B-cell depletion in human CD20 expressing
BALB/c mice in the presence or absence of human FcγR expression. (A,B)
Representative flow cytometry dot plots. Splenic mononuclear cells (MNCs) were
pre-incubated with mouse FcR blocking reagent and then incubated at 4◦C with a
combination of fluorochrome-conjugated antibodies (BD Biosciences), including
FITC-conjugated anti-CD45R/B220, and PE-conjugated anti-human CD20
(hCD20) as well as FITC-conjugated anti-mouse CD49b/DX5 and PE-conjugated
anti-human CD16 (hCD16, hFcγRIII). Cell-surface expression of hCD20 in
CD45R+ B cells was observed in hCD20-expressing mice regardless of hFcγR
expression. Cell-surface expression of hCD16 in CD49b+ NK cells was observed
in hCD20- and hFcγR-expressing mice, but not in hFcγR-negative mice. (C)
Anti-hCD20 humanized antibody TKM-011 (250 µg in 250 µL of PBS) and the
chimeric antibody rituximab (250 µg in 250 µL of PBS) or 250 µL of PBS alone
(as a control) were injected intraperitoneally into hCD20-expressing BALB/c mice
in the presence or absence of hFcγR expression. Spleens were extracted 7 days
after the injection. Splenic MNCs were counted, and an aliquot of these cells was
stained as shown above and analyzed using flow cytometry. Absolute numbers of
total CD19+ cells were calculated. Enhanced B-cell depletion was observed in
mice expressing both hCD20 and hFcγR, suggesting an in vivo functional
mechanism of hFcγR in mediating antibody-dependent cell-mediated cytotoxicity
(ADCC).
Supplementary Figure 2 | Human CD20 and FcγR-expressing B6 mice. Splenic
mononuclear cells were pre-incubated with mouse FcR blocking reagent and then
incubated at 4◦C with a combination of fluorochrome-conjugated antibodies (BD
Biosciences), including APC-conjugated anti-mouse CD19 and PE-conjugated
anti-human CD20 as well as FITC-conjugated anti-CD49b/DX5 and
PE-conjugated anti-human CD16 (hCD16, hFcγRIII). Cells were analyzed using
flow cytometry. (A) Cell-surface expression of hCD20 was observed in 47.2% of
CD19+ B cells. (B) Cell-surface expression of hCD16 was also observed in
CD49b+ NK cells.
Supplementary Figure 3 | Graphical abstract. Anti-drug antibody against a novel
humanized anti-CD20 antibody impair its therapeutic effect on primary biliary
cholangitis in human CD20- and FcγR-expressing mice.
Supplementary Figure 4 | Rituximab treatment did not ameliorate liver pathology.
Rituximab was administered using the same protocol as TKM-011 treatment in
the mouse model of PBC. (A) Anti-rituximab antibodies were observed in 6 of 7
treated mice. Serum levels of hIgG1 were gradually reduced over the course of
treatment. (B) Frequencies of CD19+ and TCR-β+ cells were transiently reduced
and increased, respectively, in rituximab-treated mice. (C) Rituximab treatment did
not improve liver inflammation or bile duct damage after 16 weeks of treatment
(n = 20 and 7 for PBS- and rituximab-treated mice, with the latter subdivided into
n = 6 anti-rituximab antibody positive mice, shown in red, and n = 1 anti-rituximab
antibody negative mouse, shown in blue. CNSDC, chronic non-suppurative
destructive cholangitis; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001 by
Mann-Whitney Test vs. PBS control and Wilcoxon Test for paired samples).
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